Sound Pharmaceuticals today announced the appointment of Paul Rickey as Chief Financial Officer (CFO). Paul Rickey, an experienced life sciences and technology industry executive, joined the company effective March 1, 2016. Paul will lead the company’s financial and administrative operations.
“Paul brings to our management team proven financial leadership and strategic corporate growth expertise that will be valuable in shaping the future of Sound Pharmaceuticals,” said Dr. Jonathan Kil, CEO. “The Board of Directors joins me in welcoming Paul to his new position as our first CFO and we look forward to his substantial contributions to our future success.”
SPI has multiple ongoing mid-stage clinical trials involving SPI-1005 or SPI-3005 in three different inner ear diseases or neurotologic indications. “The team at Sound Pharma is committed to making a difference in the lives of people suffering from hearing loss and tinnitus. I am honored to join in this mission at this exciting time of execution and growth,” commented Paul Rickey.
Prior to his appointment at Sound Pharmaceuticals, Paul served as Vice President of Finance and Administration of Immune Design Corp., a publicly traded biotechnology company where he helped complete the company’s private offerings, initial public offering, and follow-on financing. In addition, he oversaw the finance, accounting and human resource functions through July of 2015. Before joining Immune Design in 2009, Paul was Corporate Controller of Northstar Neuroscience, a publicly traded medical device company, where he managed the company’s finance and accounting groups following their IPO. Prior to his role at Northstar Neuroscience, he was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. Paul started his career at Ernst & Young LLP. He graduated from the University of Washington with a BA and Masters in Professional Accounting and is a Certified Public Accountant.
SPI is a privately held biotech in Seattle, WA developing the first drugs for the prevention and treatment of sensorineural hearing loss and tinnitus.